Novartis
NEWS
After the spring reductions in the workforce that left thousands of biotech employees searching for jobs, larger companies are, for the most part, moving forward.
Swiss biopharma giant Novartis plans to cut up to 8,000 jobs in hopes of saving at least $1 billion by 2024.
Pearl Huang, Ph.D, has been appointed the CEO of U.K.-based Dunad Therapeutics, a Novartis-backed biopharmaceutical startup.
In addition to patent cases, partnerships and pledging money to global tropical disease efforts, Novartis scored a win on a combo-treatment for solid tumors.
Funding for life sciences companies picked up this week as investors pumped new money into firms developing treatments for spinal muscular atrophy (SMA), immuno-oncology, allergies and rare diseases.
Precision BioSciences and Novartis are teaming up to develop a potential cure for hemoglobinopathies such as sickle cell disease and beta-thalassemia.
Novartis’ win in the patent dispute over its drug, Gilenya, was short-lived after a U.S. appeals court reversed its 2020 ruling vs. HEC Pharm’s attempt to create a generic version.
Decentralized clinical trials may cost more upfront, but can have huge returns on the back end, according to speakers at Informa Connect’s Decentralized Clinical Trials meeting.
It was an extraordinarily busy week for clinical trial news and updates due to several prominent international conferences. Here’s a look at some of the highlights.
JOBS
IN THE PRESS